We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
In Vivo is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
After weeks of speculation, Sanofi-Synthélabo has launched--with the support of the French government--a hostile bid to acquire its larger rival Aventis SA for €48.3bn ($60bn)--19% in cash and 81% in stock. Sanofi claims the combined pharmaco--which would be ranked the third-largest worldwide in global sales--would have one of the largest R&D budgets in the industry (at €4bn) and would feature a pipeline of almost 60 late-stage candidates. Its therapeutic focus would include cardiovascular/thrombosis, CNS, oncology, diabetes, and urology.
Deal Industry
Pharmaceuticals
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Includes Contract
Payment Includes Cash
Payment Includes Stock
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?